Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $855.00 Price Target at Morgan Stanley

Posted by Stanley Muller on Nov 2nd, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target boosted by stock analysts at Morgan Stanley from $779.00 to $855.00 in a report released on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley‘s price objective indicates a potential downside of 11.53% from the stock’s current price.

A number of other brokerages also recently issued reports on REGN. Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the company a “sector perform” rating in a research report on Monday. Truist Financial increased their price target on Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a report on Monday. HSBC raised their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Leerink Partners lifted their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research note on Monday, August 17th. Finally, Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $893.59.

Get Our Latest Analysis on REGN

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded up $38.55 on Monday, reaching $966.44. The company’s stock had a trading volume of 881,733 shares, compared to its average volume of 822,683. The company has a 50-day simple moving average of $793.30 and a 200 day simple moving average of $738.05. Regeneron Pharmaceuticals has a 52-week low of $591.52 and a 52-week high of $974.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.66 and a current ratio of 4.06. The company has a market cap of $99.50 billion, a P/E ratio of 21.35, a PEG ratio of 1.57 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm’s revenue for the quarter was up 36.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.83 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals will post 49.10 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the sale, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director directly owned 603 shares of the company’s stock, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 8,093 shares of company stock valued at $6,506,845. Corporate insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Quadcap Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at about $478,000. QTR Family Wealth LLC grew its stake in Regeneron Pharmaceuticals by 20.7% in the 3rd quarter. QTR Family Wealth LLC now owns 693 shares of the biopharmaceutical company’s stock worth $525,000 after acquiring an additional 119 shares in the last quarter. Capstone Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $262,000. Boston Trust Walden Corp increased its position in shares of Regeneron Pharmaceuticals by 794.1% during the third quarter. Boston Trust Walden Corp now owns 10,667 shares of the biopharmaceutical company’s stock worth $8,088,000 after acquiring an additional 9,474 shares during the period. Finally, Chicago Partners Investment Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 29.7% during the third quarter. Chicago Partners Investment Group LLC now owns 2,865 shares of the biopharmaceutical company’s stock valued at $2,306,000 after acquiring an additional 656 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Analysts broadly raised their forecasts following the upbeat quarter. Guggenheim increased its target to $1,100 with a “buy” rating, JPMorgan raised its target to $1,050 and assigned an “overweight” rating, and Bank of America lifted its target to $1,030 while maintaining a “buy” rating. Other firms also raised targets, with some forecasts reportedly reaching as high as $1,175. Analysts Raise Their Forecasts on Regeneron Pharmaceuticals After Upbeat Q3 Results
Positive Sentiment: The combination of 70% EPS growth, 36% revenue growth, continued Dupixent momentum, encouraging Libtayo data and an expanded BARDA Ebola-treatment supply agreement points to improving commercial execution and pipeline value. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
Positive Sentiment: Recent earnings-driven buying pushed REGN to a new one-year high, signaling strong market momentum and improved sentiment around the company’s growth outlook. Regeneron Hits 52-Week High After Standout Q3
Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3 to shareholders of record November 20. The annualized yield is approximately 0.4%, providing modest shareholder income.
Negative Sentiment: Several updated targets remain below the current trading level: RBC set $913 with a “sector perform” rating, Wells Fargo set $925 with “equal weight,” and Baird set $875 with “neutral.” These calls suggest some analysts view the recent rally as having limited near-term upside.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.